ARIUS to present at Future Leaders in the Biotech Industry conference



    TORONTO, March 28 /CNW/ - ARIUS Research Inc. (TSX: ARI), a biotechnology
company discovering and developing the next wave of antibody therapeutics,
today announced that David Young, MD, President and Chief Executive Officer,
has been invited to speak at the "Future Leaders in the Biotech Industry"
conference.
    Dr. Young will present on Thursday, March 29th at 3:00pm Eastern Time in
presentation room 304/305 and will be available following his presentation in
breakout room 310. The conference is being held at the Millennium Broadway
Hotel & Conference Center in New York, New York. Dr. Young will provide an
overview of the company's lead programs in cancer and will update the audience
on milestones leading to first in man studies and business development
activities. ARIUS has three lead programs focused on treatments for breast,
prostate, colon and pancreatic cancers.
    "Future Leaders in the Biotech Industry" features companies that are best
positioned to provide market leadership in the biotech industry. The audience
is comprised of members from the buyside and sellside investment communities.

    About ARIUS
    ARIUS is a biotechnology company discovering and developing the next wave
of antibody therapeutics. Established in 1999, ARIUS has built a proprietary
technology platform, FunctionFIRST(TM), that rapidly identifies and selects
antibodies based on their functional ability to affect disease. This antibody
generation engine has enabled ARIUS to assemble a portfolio of more than 400
antibody candidates. In addition to the antibodies it is developing in-house,
ARIUS has ongoing partnerships with key biotechnology and drug development
companies. ARUIS is listed on the TSX under the symbol "ARI". For further
information, visit www.ariusresearch.com

    Forward-Looking Statements
    Certain statements in this news release constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995, which involve known and unknown risks, uncertainties and other
factors that may cause our actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements in this release include, but are not
limited to, ARIUS successfully advancing its new product programs as well as
licensing opportunities. These statements are only predictions and actual
events or results may differ materially. Factors that could cause such actual
events or results expressed or implied by such forward-looking statements to
differ materially from any future results expressed or implied by such
statements include, but are not limited to: early stage of development;
technology and product development; dependence on and management of current
and future corporate collaborations; future capital needs; uncertainty of
additional funding; no assurance of market acceptance; dependence on
proprietary technology and uncertainty of patent protection; intense
competition; manufacturing and market uncertainties; and government
regulation. These and other factors are described in detail in ARIUS' Annual
Report, forthcoming news releases and other filings with Canadian securities
regulatory authorities available at www.sedar.com. Forward-looking statements
are based on our current expectations and ARIUS is not obligated to update
such information to reflect later events or developments.

    
     The TSX has not reviewed and does not accept responsibility for the
                   adequacy or accuracy of this statement.
    





For further information:

For further information: Helen Findlay, Executive Vice-President, (416)
862-2323 ext. 223, contact@ariusresearch.com; James Smith, Investor Relations,
(416) 815-0700 ext. 229, jsmith@equicomgroup.com

Organization Profile

ARIUS RESEARCH INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890